Author:
Boddu P,Jorgensen J,Kantarjian H,Borthakur G,Kadia T,Daver N,Alvarado Y,Pemmaraju N,Bose P,Naqvi K,Yilmaz M,Pierce S,Brandt M,DiNardo C D,Jabbour E J,Konopleva M,Garcia-Manero G,Cortes J,Ravandi F
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference16 articles.
1. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 2017; 123: 426–435.
2. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123–4131.
3. Kharfan-Dabaja MA . Guadecitabine for AML and MDS: hype or hope? Lancet Oncol 2015; 16: 1009–1011.
4. Nguyen AN, Hollenbach PW, Richard N, Luna-Moran A, Brady H, Heise C et al. Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines. Lung Cancer (Auckl) 2010; 1: 119–140.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献